Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-08-25

AUTHORS

Marina Treskova, Ines Aumann, Heiko Golpon, Jens Vogel-Claussen, Tobias Welte, Alexander Kuhlmann

ABSTRACT

BackgroundIn lung cancer screening, a nodule management protocol describes nodule assessment and thresholds for nodule size and growth rate to identify patients who require immediate diagnostic evaluation or additional imaging exams. The Netherlands-Leuvens Screening Trial and the National Lung Screening Trial used different selection criteria and nodule management protocols. Several modelling studies have reported variations in screening outcomes and cost-effectiveness across selection criteria and screening intervals; however, the effect of variations in the nodule management protocol remains uncertain. This study evaluated the effects of the eligibility criteria and nodule management protocols on the benefits, harms and cost-effectiveness of lung screening scenarios in a population-based setting in Germany.MethodsWe developed a modular microsimulation model: a biological module simulated individual histories of lung cancer development from carcinogenesis onset to death; a screening module simulated patient selection, screening-detection, nodule management protocols, diagnostic evaluation and screening outcomes. Benefits included mortality reduction, life years gained and averted lung cancer deaths. Harms were costs, false positives and overdiagnosis. The comparator was no screening. The evaluated 76 screening scenarios included variations in selection criteria and thresholds for nodule size and growth rate.ResultsFive years of annual screening resulted in a 9.7–12.8% lung cancer mortality reduction in the screened population. The efficient scenarios included volumetric assessment of nodule size, a threshold for a volume of 300 mm3 and a threshold for a volume doubling time of 400 days. Assessment of volume doubling time is essential for reducing overdiagnosis and false positives. Incremental cost-effectiveness ratios of the efficient scenarios were 16,754–23,847 euro per life year gained and 155,287–285,630 euro per averted lung cancer death.ConclusionsLung cancer screening can be cost-effective in Germany. Along with the eligibility criteria, the nodule management protocol influences screening performance and cost-effectiveness. Definition of the thresholds for nodule size and nodule growth in the nodule management protocol should be considered in detail when defining optimal screening strategies. More... »

PAGES

162

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12916-017-0924-3

DOI

http://dx.doi.org/10.1186/s12916-017-0924-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091315472

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28838313


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Early Detection of Cancer", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Germany", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mass Screening", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Netherlands", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stochastic Processes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.9122.8", 
          "name": [
            "Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Treskova", 
        "givenName": "Marina", 
        "id": "sg:person.01241640136.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241640136.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.452624.3", 
          "name": [
            "Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany", 
            "Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aumann", 
        "givenName": "Ines", 
        "id": "sg:person.01173655121.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173655121.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinics for Pneumology, Hannover Medical School, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany", 
            "Clinics for Pneumology, Hannover Medical School, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Golpon", 
        "givenName": "Heiko", 
        "id": "sg:person.01355152100.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355152100.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute for Radiology, Hannover Medical School, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany", 
            "Institute for Radiology, Hannover Medical School, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vogel-Claussen", 
        "givenName": "Jens", 
        "id": "sg:person.0624733413.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624733413.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinics for Pneumology, Hannover Medical School, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.10423.34", 
          "name": [
            "Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany", 
            "Clinics for Pneumology, Hannover Medical School, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Welte", 
        "givenName": "Tobias", 
        "id": "sg:person.01200122325.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200122325.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/grid.9122.8", 
          "name": [
            "Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuhlmann", 
        "givenName": "Alexander", 
        "id": "sg:person.01150523071.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150523071.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6605660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052402956", 
          "https://doi.org/10.1038/sj.bjc.6605660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00330-015-3697-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012075636", 
          "https://doi.org/10.1007/s00330-015-3697-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-015-0305-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053545126", 
          "https://doi.org/10.1007/s40273-015-0305-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200826090-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008652128", 
          "https://doi.org/10.2165/00019053-200826090-00004"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-08-25", 
    "datePublishedReg": "2017-08-25", 
    "description": "BackgroundIn lung cancer screening, a nodule management protocol describes nodule assessment and thresholds for nodule size and growth rate to identify patients who require immediate diagnostic evaluation or additional imaging exams. The Netherlands-Leuvens Screening Trial and the National Lung Screening Trial used different selection criteria and nodule management protocols. Several modelling studies have reported variations in screening outcomes and cost-effectiveness across selection criteria and screening intervals; however, the effect of variations in the nodule management protocol remains uncertain. This study evaluated the effects of the eligibility criteria and nodule management protocols on the benefits, harms and cost-effectiveness of lung screening scenarios in a population-based setting in Germany.MethodsWe developed a modular microsimulation model: a biological module simulated individual histories of lung cancer development from carcinogenesis onset to death; a screening module simulated patient selection, screening-detection, nodule management protocols, diagnostic evaluation and screening outcomes. Benefits included mortality reduction, life years gained and averted lung cancer deaths. Harms were costs, false positives and overdiagnosis. The comparator was no screening. The evaluated 76 screening scenarios included variations in selection criteria and thresholds for nodule size and growth rate.ResultsFive years of annual screening resulted in a 9.7\u201312.8% lung cancer mortality reduction in the screened population. The efficient scenarios included volumetric assessment of nodule size, a threshold for a volume of 300\u00a0mm3 and a threshold for a volume doubling time of 400\u00a0days. Assessment of volume doubling time is essential for reducing overdiagnosis and false positives. Incremental cost-effectiveness ratios of the efficient scenarios were 16,754\u201323,847 euro per life year gained and 155,287\u2013285,630 euro per averted lung cancer death.ConclusionsLung cancer screening can be cost-effective in Germany. Along with the eligibility criteria, the nodule management protocol influences screening performance and cost-effectiveness. Definition of the thresholds for nodule size and nodule growth in the nodule management protocol should be considered in detail when defining optimal screening strategies.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12916-017-0924-3", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7936462", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1032885", 
        "issn": [
          "1741-7015"
        ], 
        "name": "BMC Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "population-based setting", 
      "lung cancer deaths", 
      "lung cancer screening", 
      "cancer screening", 
      "cancer death", 
      "mortality reduction", 
      "diagnostic evaluation", 
      "nodule size", 
      "Screening Trial", 
      "eligibility criteria", 
      "life years", 
      "low-dose CT lung cancer screening", 
      "lung cancer mortality reduction", 
      "National Lung Screening Trial", 
      "CT lung cancer screening", 
      "management protocol", 
      "immediate diagnostic evaluation", 
      "additional imaging exams", 
      "cancer mortality reduction", 
      "incremental cost-effectiveness ratio", 
      "optimal screening strategy", 
      "lung cancer development", 
      "cost-effectiveness ratio", 
      "patient selection", 
      "annual screening", 
      "ResultsFive years", 
      "screening outcomes", 
      "selection criteria", 
      "imaging exams", 
      "volumetric assessment", 
      "cancer development", 
      "assessment of volume", 
      "screening strategy", 
      "nodule assessment", 
      "screening scenario", 
      "death", 
      "overdiagnosis", 
      "screening", 
      "trials", 
      "outcomes", 
      "years", 
      "harm", 
      "false positives", 
      "assessment", 
      "patients", 
      "microsimulation model", 
      "criteria", 
      "lung", 
      "protocol", 
      "MethodsWe", 
      "setting", 
      "benefits", 
      "evaluation", 
      "onset", 
      "volume", 
      "study", 
      "positives", 
      "management strategies", 
      "days", 
      "rate", 
      "exam", 
      "individual history", 
      "reduction", 
      "effect", 
      "threshold", 
      "mm3", 
      "nodule growth", 
      "population", 
      "interval", 
      "comparator", 
      "history", 
      "strategies", 
      "time", 
      "different selection criteria", 
      "euro", 
      "size", 
      "development", 
      "growth rate", 
      "Germany", 
      "ratio", 
      "microsimulation analysis", 
      "analysis", 
      "growth", 
      "variation", 
      "definition", 
      "effect of variation", 
      "biological modules", 
      "selection", 
      "influence", 
      "model", 
      "cost", 
      "detail", 
      "scenarios", 
      "module", 
      "performance", 
      "efficient scenario", 
      "efficiency", 
      "economic efficiency"
    ], 
    "name": "Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting", 
    "pagination": "162", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091315472"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12916-017-0924-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28838313"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12916-017-0924-3", 
      "https://app.dimensions.ai/details/publication/pub.1091315472"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_752.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12916-017-0924-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0924-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0924-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0924-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0924-3'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      21 PREDICATES      140 URIs      128 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12916-017-0924-3 schema:about N0becee51a5f846589cb8f323e0a023ef
2 N2c5d4ccf0a0c474da4efca48c38a934a
3 N309f6b43b6144494a08b3d6ee1c6fa22
4 N6c33555b870040b8ba3f9c5f4bd604de
5 N91d80de59a3e45f8a72bcf514421478b
6 N979c4c2c916c4f02ba3d4b11356c945c
7 N9dc3b0cdff1c4fcb82001fa3bebfb4db
8 N9e0c3a27df8c4896b9b92c236dcf71ed
9 Nadeaa250156141b4b8c9a2e473891130
10 Nbf0d98af1dd1417490c5ff348225901b
11 Nc3e4e7bd88824c8dae9a8bc61283d948
12 Nccab328a58714d7ba2b38d95eaec1b8f
13 Nf8df84917d344ec88c80e835eadee0ea
14 anzsrc-for:11
15 anzsrc-for:1117
16 schema:author Nc2cb6eaf30404366981be12fdd50461c
17 schema:citation sg:pub.10.1007/s00330-015-3697-0
18 sg:pub.10.1007/s40273-015-0305-8
19 sg:pub.10.1038/sj.bjc.6605660
20 sg:pub.10.2165/00019053-200826090-00004
21 schema:datePublished 2017-08-25
22 schema:datePublishedReg 2017-08-25
23 schema:description BackgroundIn lung cancer screening, a nodule management protocol describes nodule assessment and thresholds for nodule size and growth rate to identify patients who require immediate diagnostic evaluation or additional imaging exams. The Netherlands-Leuvens Screening Trial and the National Lung Screening Trial used different selection criteria and nodule management protocols. Several modelling studies have reported variations in screening outcomes and cost-effectiveness across selection criteria and screening intervals; however, the effect of variations in the nodule management protocol remains uncertain. This study evaluated the effects of the eligibility criteria and nodule management protocols on the benefits, harms and cost-effectiveness of lung screening scenarios in a population-based setting in Germany.MethodsWe developed a modular microsimulation model: a biological module simulated individual histories of lung cancer development from carcinogenesis onset to death; a screening module simulated patient selection, screening-detection, nodule management protocols, diagnostic evaluation and screening outcomes. Benefits included mortality reduction, life years gained and averted lung cancer deaths. Harms were costs, false positives and overdiagnosis. The comparator was no screening. The evaluated 76 screening scenarios included variations in selection criteria and thresholds for nodule size and growth rate.ResultsFive years of annual screening resulted in a 9.7–12.8% lung cancer mortality reduction in the screened population. The efficient scenarios included volumetric assessment of nodule size, a threshold for a volume of 300 mm3 and a threshold for a volume doubling time of 400 days. Assessment of volume doubling time is essential for reducing overdiagnosis and false positives. Incremental cost-effectiveness ratios of the efficient scenarios were 16,754–23,847 euro per life year gained and 155,287–285,630 euro per averted lung cancer death.ConclusionsLung cancer screening can be cost-effective in Germany. Along with the eligibility criteria, the nodule management protocol influences screening performance and cost-effectiveness. Definition of the thresholds for nodule size and nodule growth in the nodule management protocol should be considered in detail when defining optimal screening strategies.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N112ad4135eaf4b89a1fb903993e6d7cc
27 Ndcfd28f8081f47d78111ea3a2e298ec3
28 sg:journal.1032885
29 schema:keywords CT lung cancer screening
30 Germany
31 MethodsWe
32 National Lung Screening Trial
33 ResultsFive years
34 Screening Trial
35 additional imaging exams
36 analysis
37 annual screening
38 assessment
39 assessment of volume
40 benefits
41 biological modules
42 cancer death
43 cancer development
44 cancer mortality reduction
45 cancer screening
46 comparator
47 cost
48 cost-effectiveness ratio
49 criteria
50 days
51 death
52 definition
53 detail
54 development
55 diagnostic evaluation
56 different selection criteria
57 economic efficiency
58 effect
59 effect of variation
60 efficiency
61 efficient scenario
62 eligibility criteria
63 euro
64 evaluation
65 exam
66 false positives
67 growth
68 growth rate
69 harm
70 history
71 imaging exams
72 immediate diagnostic evaluation
73 incremental cost-effectiveness ratio
74 individual history
75 influence
76 interval
77 life years
78 low-dose CT lung cancer screening
79 lung
80 lung cancer deaths
81 lung cancer development
82 lung cancer mortality reduction
83 lung cancer screening
84 management protocol
85 management strategies
86 microsimulation analysis
87 microsimulation model
88 mm3
89 model
90 module
91 mortality reduction
92 nodule assessment
93 nodule growth
94 nodule size
95 onset
96 optimal screening strategy
97 outcomes
98 overdiagnosis
99 patient selection
100 patients
101 performance
102 population
103 population-based setting
104 positives
105 protocol
106 rate
107 ratio
108 reduction
109 scenarios
110 screening
111 screening outcomes
112 screening scenario
113 screening strategy
114 selection
115 selection criteria
116 setting
117 size
118 strategies
119 study
120 threshold
121 time
122 trials
123 variation
124 volume
125 volumetric assessment
126 years
127 schema:name Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting
128 schema:pagination 162
129 schema:productId N5e6e7bee68834409a1e16e6aa2ec9e68
130 N63db3ec792f5495993bf509a35e74e2e
131 Nb966702ac71c4867aa2904d0b9d4ca36
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091315472
133 https://doi.org/10.1186/s12916-017-0924-3
134 schema:sdDatePublished 2022-12-01T06:37
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher N15922f8e4c8d4f89b45471e4f39c9e73
137 schema:url https://doi.org/10.1186/s12916-017-0924-3
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N0becee51a5f846589cb8f323e0a023ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Male
143 rdf:type schema:DefinedTerm
144 N112ad4135eaf4b89a1fb903993e6d7cc schema:issueNumber 1
145 rdf:type schema:PublicationIssue
146 N15922f8e4c8d4f89b45471e4f39c9e73 schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 N18a0c980dbd445088414f5b90b6843d8 rdf:first sg:person.0624733413.95
149 rdf:rest N18e258c8957e4b9988ac13e490014727
150 N18e258c8957e4b9988ac13e490014727 rdf:first sg:person.01200122325.47
151 rdf:rest N79d0625a308c4983a7c6b0db33399b72
152 N2c5d4ccf0a0c474da4efca48c38a934a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Cost-Benefit Analysis
154 rdf:type schema:DefinedTerm
155 N2ca10913d62b4fdc840e56209f37e2a0 rdf:first sg:person.01355152100.09
156 rdf:rest N18a0c980dbd445088414f5b90b6843d8
157 N309f6b43b6144494a08b3d6ee1c6fa22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Humans
159 rdf:type schema:DefinedTerm
160 N5e6e7bee68834409a1e16e6aa2ec9e68 schema:name doi
161 schema:value 10.1186/s12916-017-0924-3
162 rdf:type schema:PropertyValue
163 N63db3ec792f5495993bf509a35e74e2e schema:name pubmed_id
164 schema:value 28838313
165 rdf:type schema:PropertyValue
166 N6c33555b870040b8ba3f9c5f4bd604de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Risk Assessment
168 rdf:type schema:DefinedTerm
169 N79d0625a308c4983a7c6b0db33399b72 rdf:first sg:person.01150523071.09
170 rdf:rest rdf:nil
171 N91d80de59a3e45f8a72bcf514421478b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Netherlands
173 rdf:type schema:DefinedTerm
174 N979c4c2c916c4f02ba3d4b11356c945c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Female
176 rdf:type schema:DefinedTerm
177 N9dc3b0cdff1c4fcb82001fa3bebfb4db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Tomography, X-Ray Computed
179 rdf:type schema:DefinedTerm
180 N9e0c3a27df8c4896b9b92c236dcf71ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Mass Screening
182 rdf:type schema:DefinedTerm
183 Nadeaa250156141b4b8c9a2e473891130 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Early Detection of Cancer
185 rdf:type schema:DefinedTerm
186 Nb966702ac71c4867aa2904d0b9d4ca36 schema:name dimensions_id
187 schema:value pub.1091315472
188 rdf:type schema:PropertyValue
189 Nbf0d98af1dd1417490c5ff348225901b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Patient Selection
191 rdf:type schema:DefinedTerm
192 Nc2cb6eaf30404366981be12fdd50461c rdf:first sg:person.01241640136.13
193 rdf:rest Nf09af91b8e354f59ac042fa0d9770b27
194 Nc3e4e7bd88824c8dae9a8bc61283d948 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Germany
196 rdf:type schema:DefinedTerm
197 Nccab328a58714d7ba2b38d95eaec1b8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Stochastic Processes
199 rdf:type schema:DefinedTerm
200 Ndcfd28f8081f47d78111ea3a2e298ec3 schema:volumeNumber 15
201 rdf:type schema:PublicationVolume
202 Nf09af91b8e354f59ac042fa0d9770b27 rdf:first sg:person.01173655121.06
203 rdf:rest N2ca10913d62b4fdc840e56209f37e2a0
204 Nf8df84917d344ec88c80e835eadee0ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Lung Neoplasms
206 rdf:type schema:DefinedTerm
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
211 schema:name Public Health and Health Services
212 rdf:type schema:DefinedTerm
213 sg:grant.7936462 http://pending.schema.org/fundedItem sg:pub.10.1186/s12916-017-0924-3
214 rdf:type schema:MonetaryGrant
215 sg:journal.1032885 schema:issn 1741-7015
216 schema:name BMC Medicine
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01150523071.09 schema:affiliation grid-institutes:grid.9122.8
220 schema:familyName Kuhlmann
221 schema:givenName Alexander
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150523071.09
223 rdf:type schema:Person
224 sg:person.01173655121.06 schema:affiliation grid-institutes:grid.452624.3
225 schema:familyName Aumann
226 schema:givenName Ines
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173655121.06
228 rdf:type schema:Person
229 sg:person.01200122325.47 schema:affiliation grid-institutes:grid.10423.34
230 schema:familyName Welte
231 schema:givenName Tobias
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200122325.47
233 rdf:type schema:Person
234 sg:person.01241640136.13 schema:affiliation grid-institutes:grid.9122.8
235 schema:familyName Treskova
236 schema:givenName Marina
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241640136.13
238 rdf:type schema:Person
239 sg:person.01355152100.09 schema:affiliation grid-institutes:grid.10423.34
240 schema:familyName Golpon
241 schema:givenName Heiko
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355152100.09
243 rdf:type schema:Person
244 sg:person.0624733413.95 schema:affiliation grid-institutes:grid.10423.34
245 schema:familyName Vogel-Claussen
246 schema:givenName Jens
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624733413.95
248 rdf:type schema:Person
249 sg:pub.10.1007/s00330-015-3697-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012075636
250 https://doi.org/10.1007/s00330-015-3697-0
251 rdf:type schema:CreativeWork
252 sg:pub.10.1007/s40273-015-0305-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053545126
253 https://doi.org/10.1007/s40273-015-0305-8
254 rdf:type schema:CreativeWork
255 sg:pub.10.1038/sj.bjc.6605660 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052402956
256 https://doi.org/10.1038/sj.bjc.6605660
257 rdf:type schema:CreativeWork
258 sg:pub.10.2165/00019053-200826090-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008652128
259 https://doi.org/10.2165/00019053-200826090-00004
260 rdf:type schema:CreativeWork
261 grid-institutes:grid.10423.34 schema:alternateName Clinics for Pneumology, Hannover Medical School, Hannover, Germany
262 Institute for Radiology, Hannover Medical School, Hannover, Germany
263 schema:name Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany
264 Clinics for Pneumology, Hannover Medical School, Hannover, Germany
265 Institute for Radiology, Hannover Medical School, Hannover, Germany
266 rdf:type schema:Organization
267 grid-institutes:grid.452624.3 schema:alternateName Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany
268 schema:name Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany
269 Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany
270 rdf:type schema:Organization
271 grid-institutes:grid.9122.8 schema:alternateName Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany
272 schema:name Center for Health Economics Research Hannover (CHERH), Leibniz University of Hannover, Otto-Brenner-Str.1, 30159, Hannover, Germany
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...